Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Compass Pathways Plc (CMPS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Compass Pathways's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
8.25 -0.23    -2.71%
21:00:29 - Closed. Currency in USD ( Disclaimer )
After Hours
8.45
+0.20
+2.42%
21:51:37 - Real-time Data
  • Volume: 244,378
  • Bid/Ask: 8.06 / 8.44
  • Day's Range: 8.18 - 8.78
Type:  Equity
Market:  United States
Compass Pathways 8.25 -0.23 -2.71%

Compass Pathways Company Profile

 
Read the Compass Pathways Plc company profile to learn more about the business and the management team. View Compass Pathways Plc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

186

Equity Type

ORD

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Contact Information

Address 33 Broadwick Street
London, W1F 0DQ
United Kingdom
Phone 44 71 6676 6461
Fax -

Top Executives

Name Age Since Title
David York Norton 73 2018 Independent Chairman & Lead Independent Director
Thomas Lonngren 74 2018 Independent Non-Executive Director
Annalisa Mary Jenkins 59 2018 Independent Non-Executive Director
Kabir Nath 60 2022 CEO & Director
Linda R. McGoldrick 69 2020 Independent Non Executive Director
Kirk Rutter - - Special Advisor of Patient Experience
Daphne Karydas 51 2023 Independent Director
Alan F. Schatzberg 79 - Member of Scientific Advisory Network
Paul Summergrad - - Member of Scientific Advisory Network
Thomas R. Insel 71 - Member of Scientific Advisory Network
Diego Pizzagalli - - Member of Scientific Advisory Network
Robert D. McQuade 67 2020 Independent Non Executive Director
Gul Dolen - - Member of Scientific Advisory Network
John Rush - - Member of Scientific Advisory Network
Wayne Joseph Riley 65 2021 Independent Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CMPS Price Commentary

Write your thoughts about Compass Pathways Plc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Nick Wade
Nick Wade Jun 15, 2022 8:20
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Excellent long term hold buy on dips
Þorlákur Arnason
Þorlákur Arnason Dec 29, 2021 17:08
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This stock will go to plus 100 in 2022
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email